A phase I / IIa trial of PXS-5505, a novel pan-lysyl oxidase inhibitor, in advanced myelofibrosis

Myelofibrosis (MF) is a progressive disease characterized by accumulation of extracellular matrix (ECM) in the bone marrow (BM) which impairs normal hematopoiesis. While Janus kinase (JAK) inhibitors reduce spleen volume and provide symptomatic improvement, they do not resolve BM fibrosis and may c...

Descrición completa

Detalles Bibliográficos

Principais autores:	Pankit Vachhani, Peter Tan, Anne-Marie Watson, Shang-Ju Wu, Ross Baker, Stanley Cheung, Sung-Eun Lee, Chih-Cheng Chen, Tsai-Yun Chen, Hui-Hua Hsiao, Jae Hoon Lee, Lucia Masarova, Shuh Ying Tan, Jana Baskar, Brett Charlton, Alison Findlay, Dieter Hamprecht, Wolfgang Jarolimek, Joanna Leadbetter, John Miller, Kristen Morgan, Amna Zahoor, Gabriela Hobbs
Formato:	Artigo
Idioma:	Inglês
Publicado:	Ferrata Storti Foundation 2025-04-01
Series:	Haematologica
Acceso en liña:	https://haematologica.org/article/view/12032
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!